Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder
BackgroundSeveral studies have reported the efficacy and safety of rituximab (RTX) and mycophenolate mofetil (MMF) in neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the efficacy and safety of long-term use of low-dose RTX and MMF in Chinese patients with NMOSD.MethodsWe...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.891064/full |
| _version_ | 1818269716831010816 |
|---|---|
| author | Jie Lin Binbin Xue Jia Li Ruofan Zhu Juyuan Pan Zhibo Chen Xu Zhang Xiang Li Junhui Xia |
| author_facet | Jie Lin Binbin Xue Jia Li Ruofan Zhu Juyuan Pan Zhibo Chen Xu Zhang Xiang Li Junhui Xia |
| author_sort | Jie Lin |
| collection | DOAJ |
| description | BackgroundSeveral studies have reported the efficacy and safety of rituximab (RTX) and mycophenolate mofetil (MMF) in neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the efficacy and safety of long-term use of low-dose RTX and MMF in Chinese patients with NMOSD.MethodsWe retrospectively reviewed data from patients with NMOSD in our hospital. The enrolled patients were administrated different immunosuppressive agents. We accessed annual relapse rate (ARR), neurological disability (Expanded Disability Status Scale, EDSS), time to the next relapse, and adverse events.ResultsEDSS and ARR were both reduced after RTX and MMF treatment. Kaplan-Meier analysis indicated that patients treated with RTX had a longer time to next relapse compared other immunosuppressive agents before RTX (log-rank test: p < 0.001). Furthermore, we evaluated the change of EDSS and ARR in RTX and MMF, and patients treated with RTX showed a better reduction. Eleven relapses from seven patients in group RTX and 20 relapses from 14 patients in group MMF were reported during follow-up.ConclusionLong-term using of low dose of RTX and MMF were effective and tolerable in Chinese patients with NMOSD. Compared with MMF, RTX showed a better way to reduce the ARR. |
| first_indexed | 2024-12-12T20:58:49Z |
| format | Article |
| id | doaj.art-61ad1f4aef3c4667af5c46d314f20da6 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-12T20:58:49Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-61ad1f4aef3c4667af5c46d314f20da62022-12-22T00:12:13ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-05-011310.3389/fneur.2022.891064891064Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum DisorderJie Lin0Binbin Xue1Jia Li2Ruofan Zhu3Juyuan Pan4Zhibo Chen5Xu Zhang6Xiang Li7Junhui Xia8Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaBackgroundSeveral studies have reported the efficacy and safety of rituximab (RTX) and mycophenolate mofetil (MMF) in neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the efficacy and safety of long-term use of low-dose RTX and MMF in Chinese patients with NMOSD.MethodsWe retrospectively reviewed data from patients with NMOSD in our hospital. The enrolled patients were administrated different immunosuppressive agents. We accessed annual relapse rate (ARR), neurological disability (Expanded Disability Status Scale, EDSS), time to the next relapse, and adverse events.ResultsEDSS and ARR were both reduced after RTX and MMF treatment. Kaplan-Meier analysis indicated that patients treated with RTX had a longer time to next relapse compared other immunosuppressive agents before RTX (log-rank test: p < 0.001). Furthermore, we evaluated the change of EDSS and ARR in RTX and MMF, and patients treated with RTX showed a better reduction. Eleven relapses from seven patients in group RTX and 20 relapses from 14 patients in group MMF were reported during follow-up.ConclusionLong-term using of low dose of RTX and MMF were effective and tolerable in Chinese patients with NMOSD. Compared with MMF, RTX showed a better way to reduce the ARR.https://www.frontiersin.org/articles/10.3389/fneur.2022.891064/fullneuromyelitis optica spectrum disorderrituximabmycophenolate mofetilEDSSannual relapse rate |
| spellingShingle | Jie Lin Binbin Xue Jia Li Ruofan Zhu Juyuan Pan Zhibo Chen Xu Zhang Xiang Li Junhui Xia Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder Frontiers in Neurology neuromyelitis optica spectrum disorder rituximab mycophenolate mofetil EDSS annual relapse rate |
| title | Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder |
| title_full | Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder |
| title_fullStr | Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder |
| title_full_unstemmed | Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder |
| title_short | Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder |
| title_sort | comparison of long term use of low dose rituximab and mycophenolate mofetil in chinese patients with neuromyelitis optica spectrum disorder |
| topic | neuromyelitis optica spectrum disorder rituximab mycophenolate mofetil EDSS annual relapse rate |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.891064/full |
| work_keys_str_mv | AT jielin comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT binbinxue comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT jiali comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT ruofanzhu comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT juyuanpan comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT zhibochen comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT xuzhang comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT xiangli comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder AT junhuixia comparisonoflongtermuseoflowdoserituximabandmycophenolatemofetilinchinesepatientswithneuromyelitisopticaspectrumdisorder |